New drug trial targets hardened skin in rare autoimmune disease
NCT ID NCT07287670
Summary
This study is testing an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and hardening. About 85 participants will be randomly assigned to receive either the drug or a placebo via an IV infusion every four weeks for 20 weeks. The main goal is to see if the drug safely reduces skin thickness and to understand how the body processes it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
EncompaSSc site in Clearwater, FL 33765
Clearwater, Florida, 33765, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
EncompaSSc site in Newport Beach, CA 92663
Newport Beach, California, 92663, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.